Office of Commercialization and Economic Development
Office of Technology Commercialization

IL23 Cytokine T Cell Engineering for Cancer Immunotherapy

Technology #19-0145

The development of inducible and selective engineering processes supporting T cell expansion and survival remain critical in adoptive T cell therapies in solid tumors. IL23 is a heterodimeric cytokine that consists of p19 and p40 subunits, both expressed by activated macrophages and dendritic cells. Activation-induced expression of the p19 subunit in T cells couples the release and activity of IL23 with T cell activation by supplementing the p40 subunit to T cells, p40-expressing T(p40-Td) cells produce IL23 upon T cell activation, which drives T cell proliferation and survival in an activation-specific manner.

Related Publications: